

treatment of hospitalized patients with COVID-19. Given the issuance of this EUA, FDA is issuing a new guidance of the same title that provides recommendations and additional information related to the EUA for the use of COVID-19 convalescent plasma to treat hospitalized patients with COVID-19. The new guidance supersedes the May 2020 guidance. Elsewhere in this issue of the **Federal Register**, FDA is announcing the availability of the new guidance.

Dated: September 16, 2020.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2020-20801 Filed 9-18-20; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Request for Information: STI National Strategic Plan 2021–2025 Available for Public Comment

**AGENCY:** Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) Office of Infectious Disease and HIV/AIDS Policy (OIDP) in the Office of the Assistant Secretary for Health (OASH) announces the draft Sexually Transmitted Infections National Strategic Plan 2021–2025 (STI Plan) available for public comment. The draft STI Plan may be reviewed at [www.hhs.gov/STI](http://www.hhs.gov/STI).

**DATES:** All comments must be received by 5:00 p.m. ET on October 1, 2020 to ensure consideration.

**ADDRESSES:** All comments must be submitted electronically to [STDPlan@hhs.gov](mailto:STDPlan@hhs.gov).

**FOR FURTHER INFORMATION CONTACT:** Carol Jimenez, OIDP, [Carol.Jimenez@hhs.gov](mailto:Carol.Jimenez@hhs.gov), 202-401-5131.

**SUPPLEMENTARY INFORMATION:** Persistent rises in the rates of sexually transmitted infections (STIs) in the United States constitute an epidemic and public health crisis with profound implications for all Americans. In recent decades, rates of chlamydia, gonorrhea, syphilis, congenital syphilis, and human papillomavirus have increased significantly. The rate of chlamydia, the most prevalent STI, increased by greater than 200% from 2011 to 2018.<sup>1</sup> In just over a decade, the rate of gonorrhea rose by greater than 80% from a historic low. The rates of primary and secondary syphilis and of congenital syphilis increased every year since 2001 and

2012, respectively.<sup>2</sup> Human papillomavirus (HPV), the most common STI, accounts for 14 million new STI infections each year.<sup>3</sup> Left untreated, STIs can lead to significant health consequences.

To spur action to reduce STI rates and their adverse public health impact, OASH through OIDP, in collaboration with federal partners throughout HHS and other departments, led and coordinated development of the inaugural STI Plan. Opportunities for public input were provided, and public comments received were reviewed, and analyzed and helped inform the components of the STI Plan.

The STI Plan is intended to serve as a roadmap for all stakeholders at all levels to guide development of policies, initiatives, and actions for STI prevention and control. The STI Plan focuses on four of the STIs that have the greatest impact on the health of the nation: chlamydia, gonorrhea, syphilis, and HPV. However, most of its components are also applicable to other prevalent STIs.

The STI Plan presents a strategic framework for integrating and leveraging synergistic policies, programs, and resources. It sets forth a vision and goals for the nation, with objectives and strategies for each goal. The objectives and strategies offered in this plan are interrelated and may be used to make progress toward more than one goal. The STI Plan identifies priority populations (*i.e.*, those populations disproportionately impacted by STIs based on national data) to guide national efforts to realize the highest impact on reducing STIs. The STI Plan also includes indicators to measure progress and quantitative targets for each indicator. Although it is a 5-year plan, it sets 10-year quantitative targets for each indicator—reflecting the reality that it will take more than 5 years to reverse, not just slow, the upward trajectory of rising STI rates, and to eliminate the epidemic. The order in which the goals, objectives, strategies, and indicators are presented is not associated with any prioritization.

The following are the STI Plan's vision and goals. *Vision:* The United States will be a place where sexually transmitted infections are prevented and where every person has high-quality STI prevention, care, and treatment while living free from stigma and discrimination. This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, disability, geographic location, or socioeconomic circumstance. *Goals:*

1. Prevent new STIs

2. Improve the health of people by reducing adverse outcomes of STIs
3. Accelerate progress in STI research, technology, and innovation
4. Reduce STI-related health disparities and health inequities
5. Achieve integrated, coordinated efforts that address the STI epidemic

A roadmap for stakeholders at all levels and sectors, the STI Plan envisions a whole-of-nation response to preventing and controlling STIs in the United States. The STI Plan assumes the active participation of state, local, and tribal health departments and organizations, health plans and health care providers, schools and other academic institutions, community- and faith-based organizations, scientists, researchers, and the public in this effort. The priority populations, indicators, and quantitative targets, especially the methods used to determine them, are intended to help focus efforts and limited resources to realize the most impact. Stakeholders are encouraged to focus on activities that resonate the most with the needs of the populations they serve and services they provide, and, using the STI Plan as a framework, develop their own plans to reverse the rise of STIs and improve the health of their communities, states, tribal nations, and the nation.

#### Information Needs

The draft STI Plan may be reviewed at: [www.hhs.gov/STI](http://www.hhs.gov/STI).

OIDP seeks to obtain feedback from external stakeholders on the following:

1. Do the draft plan's goals, objectives, and strategies appropriately address the STI epidemic?
2. Are there any critical gaps in the STI Plan's goals, objectives, and strategies? If so, please specify the gaps.
3. Do any of the STI Plan's goals, objectives and strategies cause concern? If so, please specify the goal, objective or strategy, and describe the concern regarding it.

Please be succinct and limit your comments to a maximum of seven pages.

**Authority:** 77 FR 15761 (March 16, 2012).

Dated: September 15, 2020.

**B. Kaye Hayes,**

*Acting Director, Office of Infectious Disease and HIV/AIDS Policy.*

#### Footnotes

1. Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2018*. U.S. Department of Health and Human Services; 2019. Accessed June 22, 2020. <https://www.cdc.gov/std/>

*stats18/STDSurveillance2018-full-report.pdf*

2. Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2018*. U.S. Department of Health and Human Services; 2019. Accessed June 22, 2020. <https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf>
3. About HPV. Centers for Disease Control and Prevention. Accessed July 14, 2020. <https://www.cdc.gov/hpv/parents/about-hpv.html>

[FR Doc. 2020-20677 Filed 9-18-20; 8:45 am]

BILLING CODE 4150-43-P

## DEPARTMENT OF HOMELAND SECURITY

### U.S. Customs and Border Protection

[Docket No. USCBP-2020-0053]

#### Commercial Customs Operations Advisory Committee (COAC); Meeting

**AGENCY:** U.S. Customs and Border Protection (CBP), Department of Homeland Security (DHS).

**ACTION:** Committee Management; notice of Federal Advisory Committee meeting.

**SUMMARY:** The Commercial Customs Operations Advisory Committee (COAC) will hold its quarterly meeting on Wednesday, October 7, 2020. The meeting will be open to the public via webinar only. There is no on-site, in-person option for this quarterly meeting.

**DATES:** The COAC will meet on Wednesday, October 7, 2020, from 1:00 p.m. to 5:00 p.m. EDT. Please note that the meeting may close early if the committee has completed its business. Comments must be submitted in writing no later than October 6, 2020.

**ADDRESSES:** The meeting will be held via webinar. The webinar link and conference number will be provided to all registrants by 10:00 a.m. EDT on October 7, 2020. For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs and Border Protection (CBP), at (202) 344-1440, as soon as possible.

**FOR FURTHER INFORMATION CONTACT:** Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW, Room 3.5A, Washington, DC 20229; telephone (202) 344-1440; or Ms. Valarie Neuhart, Deputy Executive Director and Designated Federal Officer, at (202) 344-1440.

**SUPPLEMENTARY INFORMATION:** Notice of this meeting is given under the authority of the Federal Advisory Committee Act, 5 U.S.C. Appendix. The Commercial Customs Operations Advisory Committee (COAC) provides advice to the Secretary of Homeland Security, the Secretary of the Treasury, and the Commissioner of U.S. Customs and Border Protection (CBP) on matters pertaining to the commercial operations of CBP and related functions within the Department of Homeland Security and the Department of the Treasury.

**Pre-registration:** For members of the public who plan to participate via webinar, please register online at <https://teregistration.cbp.gov/index.asp?w=211> by 5:00 p.m. EDT by October 6, 2020. For members of the public who are pre-registered to attend the webinar and later need to cancel, please do so by October 6, 2020, utilizing the following link: <https://teregistration.cbp.gov/cancel.asp?w=211>.

Please feel free to share this information with other interested members of your organization or association.

To facilitate public participation, we are inviting public comment on the issues the committee will consider prior to the formulation of recommendations as listed in the Agenda section below.

Comments must be submitted in writing no later than October 6, 2020, and must be identified by Docket No. USCBP-2020-0053, and may be submitted by one (1) of the following methods:

- **Federal eRulemaking Portal:** <http://www.regulations.gov>. Follow the instructions for submitting comments.

- **Email:** [tradeevents@cbp.dhs.gov](mailto:tradeevents@cbp.dhs.gov). Include the docket number in the subject line of the message.

- **Mail:** Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW, Room 3.5A, Washington, DC 20229.

**Instructions:** All submissions received must include the words "Department of Homeland Security" and the docket number (USCBP-2020-0053) for this action. Comments received will be posted without alteration at <http://www.regulations.gov>. Please do not submit personal information to this docket.

**Docket:** For access to the docket or to read background documents or comments, go to <http://www.regulations.gov> and search for Docket Number USCBP-2020-0053. To submit a comment, click the "Comment Now!" button located on the top-right hand side of the docket page.

There will be multiple public comment periods held during the meeting on October 7, 2020. Speakers are requested to limit their comments to two (2) minutes or less to facilitate greater participation. Please note that the public comment period for speakers may end before the time indicated on the schedule that is posted on the CBP web page, <http://www.cbp.gov/trade/stakeholder-engagement/coac>.

#### Agenda

The COAC will hear from the current subcommittees on the topics listed below and then will review, deliberate, provide observations, and formulate recommendations on how to proceed:

1. The Intelligent Enforcement Subcommittee will discuss its White Paper on Enforcement Modernization to support CBP's 21st Century Customs Framework, which aims to further improve risk management and the impact of efforts to detect high-risk activity, deter non-compliance, and disrupt fraudulent behavior by better utilizing technology, big data, and predictive analysis to drive decision-making. The subcommittee also will discuss prioritized past recommendations and any new recommendations from the Anti-Dumping/Countervailing Duty (AD/CVD), Bond, Intellectual Property Rights (IPR), and Forced Labor Working Groups. The Forced Labor Working Group will present recommendations on CBP's existing forced labor allegations submission mechanisms including the e-Allegations web portal.

2. The Secure Trade Lanes Subcommittee will provide updates on the Trusted Trader Working Group's activities specific to the CTPAT Trade Compliance program enhancements including benefits, Participating Government Agency engagement, and forced labor. The Export Modernization Working Group will provide updates and recommendations focusing on improving current export processes. The subcommittee will also report on the activities of the Remote and Autonomous Cargo Processing Working Group.

3. The Next Generation Facilitation Subcommittee will provide an update on the progress of the One U.S. Government Working Group with Partner Government Agencies regarding advancement in Trusted Trader initiatives. There will be an update on the progress of the Unified Entry Processing Working Group's operational framework. Finally the Emerging Technologies Working Group will provide an assessment of various technologies evaluated this past quarter